399 related articles for article (PubMed ID: 28960303)
1. Interstitial IgG antibody pharmacokinetics assessed by combined in vivo- and physiologically-based pharmacokinetic modelling approaches.
Eigenmann MJ; Karlsen TV; Krippendorff BF; Tenstad O; Fronton L; Otteneder MB; Wiig H
J Physiol; 2017 Dec; 595(24):7311-7330. PubMed ID: 28960303
[TBL] [Abstract][Full Text] [Related]
2. Tissue Distribution of a Therapeutic Monoclonal Antibody Determined by Large Pore Microdialysis.
Jadhav SB; Khaowroongrueng V; Fueth M; Otteneder MB; Richter W; Derendorf H
J Pharm Sci; 2017 Sep; 106(9):2853-2859. PubMed ID: 28414146
[TBL] [Abstract][Full Text] [Related]
3. Towards a platform PBPK model to characterize the plasma and tissue disposition of monoclonal antibodies in preclinical species and human.
Shah DK; Betts AM
J Pharmacokinet Pharmacodyn; 2012 Feb; 39(1):67-86. PubMed ID: 22143261
[TBL] [Abstract][Full Text] [Related]
4. Physiologically-based pharmacokinetic (PBPK) model to predict IgG tissue kinetics in wild-type and FcRn-knockout mice.
Garg A; Balthasar JP
J Pharmacokinet Pharmacodyn; 2007 Oct; 34(5):687-709. PubMed ID: 17636457
[TBL] [Abstract][Full Text] [Related]
5. Scale-up of a physiologically-based pharmacokinetic model to predict the disposition of monoclonal antibodies in monkeys.
Glassman PM; Chen Y; Balthasar JP
J Pharmacokinet Pharmacodyn; 2015 Oct; 42(5):527-40. PubMed ID: 26364301
[TBL] [Abstract][Full Text] [Related]
6. Clinical validation of translational antibody PBPK model using tissue distribution data generated with
Liu S; Li Z; Huisman M; Shah DK
J Pharmacokinet Pharmacodyn; 2023 Oct; 50(5):377-394. PubMed ID: 37382712
[TBL] [Abstract][Full Text] [Related]
7. Second-generation minimal physiologically-based pharmacokinetic model for monoclonal antibodies.
Cao Y; Balthasar JP; Jusko WJ
J Pharmacokinet Pharmacodyn; 2013 Oct; 40(5):597-607. PubMed ID: 23996115
[TBL] [Abstract][Full Text] [Related]
8. Physiologically based pharmacokinetic model for specific and nonspecific monoclonal antibodies and fragments in normal tissues and human tumor xenografts in nude mice.
Baxter LT; Zhu H; Mackensen DG; Jain RK
Cancer Res; 1994 Mar; 54(6):1517-28. PubMed ID: 8137258
[TBL] [Abstract][Full Text] [Related]
9. Pharmacokinetics of monoclonal immunoglobulin G1, F(ab')2, and Fab' in mice.
Covell DG; Barbet J; Holton OD; Black CD; Parker RJ; Weinstein JN
Cancer Res; 1986 Aug; 46(8):3969-78. PubMed ID: 3731067
[TBL] [Abstract][Full Text] [Related]
10. Development of a physiologically-based pharmacokinetic model for ocular disposition of monoclonal antibodies in rabbits.
Bussing D; K Shah D
J Pharmacokinet Pharmacodyn; 2020 Dec; 47(6):597-612. PubMed ID: 32876799
[TBL] [Abstract][Full Text] [Related]
11. Development of a PBPK model for monoclonal antibodies and simulation of human and mice PBPK of a radiolabelled monoclonal antibody.
Heiskanen T; Heiskanen T; Kairemo K
Curr Pharm Des; 2009; 15(9):988-1007. PubMed ID: 19275663
[TBL] [Abstract][Full Text] [Related]
12. Comparison of monoclonal antibody disposition predictions using different physiologically based pharmacokinetic modelling platforms.
De Sutter PJ; Gasthuys E; Vermeulen A
J Pharmacokinet Pharmacodyn; 2023 Nov; ():. PubMed ID: 37952005
[TBL] [Abstract][Full Text] [Related]
13. Physiologically Based Pharmacokinetic Modeling to Characterize the Effect of Molecular Charge on Whole-Body Disposition of Monoclonal Antibodies.
Liu S; Shah DK
AAPS J; 2023 Apr; 25(3):48. PubMed ID: 37118220
[TBL] [Abstract][Full Text] [Related]
14. The interstitial distribution of macromolecules in rat tumours is influenced by the negatively charged matrix components.
Wiig H; Gyenge CC; Tenstad O
J Physiol; 2005 Sep; 567(Pt 2):557-67. PubMed ID: 15994186
[TBL] [Abstract][Full Text] [Related]
15. Antibody biodistribution coefficients: inferring tissue concentrations of monoclonal antibodies based on the plasma concentrations in several preclinical species and human.
Shah DK; Betts AM
MAbs; 2013; 5(2):297-305. PubMed ID: 23406896
[TBL] [Abstract][Full Text] [Related]
16. Physiologically-based pharmacokinetic modeling to predict the clinical pharmacokinetics of monoclonal antibodies.
Glassman PM; Balthasar JP
J Pharmacokinet Pharmacodyn; 2016 Aug; 43(4):427-46. PubMed ID: 27377311
[TBL] [Abstract][Full Text] [Related]
17. Minimal Physiologically-based Pharmacokinetic Model to Investigate the Effect of Charge on the Pharmacokinetics of Humanized anti-HCV-E2 IgG Antibodies in Sprague-Dawley Rats.
Hardiansyah D; Ng CM
Pharm Res; 2022 Mar; 39(3):481-496. PubMed ID: 35246757
[TBL] [Abstract][Full Text] [Related]
18. The pharmacokinetics of the interstitial space in humans.
Levitt DG
BMC Clin Pharmacol; 2003 Jul; 3():3. PubMed ID: 12890292
[TBL] [Abstract][Full Text] [Related]
19. Quantification of IgG monoclonal antibody clearance in tissues.
Eigenmann MJ; Fronton L; Grimm HP; Otteneder MB; Krippendorff BF
MAbs; 2017; 9(6):1007-1015. PubMed ID: 28613103
[TBL] [Abstract][Full Text] [Related]
20. Development and evaluation of a generic physiologically based pharmacokinetic model for children.
Edginton AN; Schmitt W; Willmann S
Clin Pharmacokinet; 2006; 45(10):1013-34. PubMed ID: 16984214
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
